Variables | Mucinous carcinoma | Mucinous carcinoma with infiltrative invasion | Mucinous carcinoma with expansile invasion | High-grade serous carcinoma | p-value a | p-value b | p-value c | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
n =52 | n = 27 | n = 25 | n = 219 | ||||||||
Age (years) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Median ± SD | 49.9 ± 17.7 | 52.6 ± 17.3 | 47.0 ± 18.0 | 58.2 ± 11.5 | <0.01 | 0.11 | <0.01 | ||||
≥60 | 18 | (34.6) | 10 | (37.0) | 8 | (32.0) | 101 | (46.1) | 0.16 | 0.42 | 0.21 |
<60 | 34 | (65.4) | 17 | (63.0) | 17 | (68.0) | 118 | (53.9) | Â | Â | Â |
FIGO stage (%) | Â | Â | Â | Â | Â | Â | Â | Â | <0.01 | <0.01 | <0.01 |
I | 36 | (69.2) | 16 | (59.3) | 20 | (80.0) | 23 | (10.5) | Â | Â | Â |
II | 3 | (5.8) | 1 | (3.7) | 2 | (8.0) | 18 | (8.2) | Â | Â | Â |
III | 8 | (15.4) | 7 | (25.9) | 1 | (4.0) | 126 | (57.5) | Â | Â | Â |
IV | 5 | (9.6) | 3 | (11.1) | 2 | (8.0) | 52 | (23.7) | Â | Â | Â |
Peritoneal cytology (%) | Â | Â | Â | Â | Â | Â | Â | Â | <0.01 | <0.01 | <0.01 |
Positive | 24 | (46.2) | 14 | (51.9) | 10 | (40.0) | 178 | (81.3) | Â | Â | Â |
Negative | 28 | (53.8) | 13 | (48.1) | 15 | (60.0) | 41 | (18.7) | Â | Â | Â |
Residual tumor at PDS (%) | Â | Â | Â | Â | Â | Â | Â | Â | <0.01 | <0.01 | <0.01 |
Yes | 13 | (25.0) | 9 | (33.3) | 4 | (16.0) | 152 | (69.4) | Â | Â | Â |
No | 39 | (75.0) | 18 | (66.7) | 21 | (84.0) | 67 | (30.6) | Â | Â | Â |
Adjuvant chemotherapy (%) | Â | Â | Â | Â | Â | Â | Â | Â | <0.01 | <0.01 | <0.01 |
Taxane-platinum therapy | 8 | (15.4) | 6 | (22.2) | 2 | (8.0) | 132 | (60.3) | Â | Â | Â |
Platinum-based therapy | 26 | (50.0) | 16 | (59.3) | 10 | (40.0) | 65 | (29.7) | Â | Â | Â |
Not administered | 18 | (34.6) | 5 | (18.5) | 13 | (52.0) | 22 | (10.0) | Â | Â | Â |
Response rate (%) d | Â | Â | Â | Â | Â | Â | Â | Â | 0.14 | 0.02 | 0.99 |
CR/PR | 6 | (54.5) | 3 | (37.5) | 3 | (100.0) | 105 | (77.2) | Â | Â | Â |
SD/PD | 5 | (45.5) | 5 | (62.5) | 0 | (0.0) | 31 | (22.8) | Â | Â | Â |